@misc{oai:repo.qst.go.jp:00074881,
 author = {島田, 斉 and Shimada, Hitoshi},
 month = {Mar},
 note = {Objectives: 
Abnormal accumulations of tau proteins are pathognomonic hallmarks of 4-repeat tauopathies represented by progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). The aim of this study is to investigate the characteristic pattern of 18F-PM-PBB3 uptake and its relationship with clinical symptoms and neurodegeneration in patients with clinically diagnosed patients with 4-repeat tauopathies.
Methods: 
17 patients with 4-repeat tauopathies, including PSP-Richardson syndrome (PSP-RS), PSP-parkinsonism (PSP-P), PSP-progressive non-fluent aphasia (PSP-PNFA), PSP-behavior variant frontotemporal dementia (PSP-bvFTD), corticobasal syndrome-progressive non-fluent aphasia (CBS-PNFA), and biopsy-confirmed CBD, were recruited. Seven Alzheimer’s disease (AD) spectrum patients and 29 cognitively healthy controls (HCs) were also enrolled. All participants underwent PET scans with 18F-PM-PBB3 and 11C-PiB for evaluating regional tau and Aβ depositions. Parametric 18F-PM-PBB3- and 11C-PiB- images were generated by voxel-based calculation of standard standardized uptake value ratio (SUVR) to the cerebellum.
Results: 
PiB-negative patients with 4-repeat tauopathies showed remarkable uptake of PM-PBB3 especially around subthalamic nucleus, basal ganglia and brainstem. Compared with PSP-RS, patients with PSP-P and CBD showed relatively milder PM-PBB3 uptake around brainstem. In contrast, patients with 4-repeat tauopathies having verbal and/or behavior symptoms presented elevated PM-PBB3 uptake also in some cortices. Patients with 4-repeat tauopathies were easily differentiated from AD spectrum patients as well as HCs both by visual assessment and quantitative comparison of SUVR values in some brain regions.
Conclusions: 
Accumulations of PM-PBB3 would reflect characteristic distributions of tau pathologies in 4-repeat tauopathies. The present study would provide further evidence for the potential utility of 18F-PM-PBB3 PET in tracking 4-repeat tau pathologies., ADPD2019},
 title = {In vivo uptake of 18F-PM-PBB3 in patients with diverse 4-repeat tauopathies},
 year = {2019}
}